Rucaparib camsylate

About Rucaparib camsylate (CAS 1859053-21-6)

Rucaparib camsylate, also known as PF-01367338 and PF 01367338, is a small molecule PARP inhibitor widely used in oncology and DNA repair research. Identified under CAS 1859053-21-6, this compound is associated with targeted inhibition of poly(ADP-ribose) polymerase enzymes, which play a critical role in DNA damage response pathways. Rucaparib camsylate Pfizer development programs contributed to its recognition as an important reference compound in studies of cancer cell sensitivity and genomic stability.

Researchers frequently analyze Rucaparib camsylate chemical structure to better understand its interaction with PARP enzymes and its binding efficiency. In addition, Rucaparib camsylate molecular weight is a key parameter considered during assay preparation, ensuring consistency in compound handling and experimental reproducibility.

Application Rucaparib camsylate

Application Rucaparib camsylate is primarily focused on oncology research and studies involving DNA repair mechanisms. It is widely used to investigate synthetic lethality in tumor cells with defective homologous recombination pathways.

• evaluation of PARP inhibition in cancer cell models
• study of DNA repair pathways and genomic instability
• screening of compounds targeting DNA damage response mechanisms

These applications make PF-01367338 a valuable tool for both mechanistic studies and drug discovery workflows in oncology.

In Vitro

In vitro, Rucaparib camsylate is commonly applied in cell-based assays to assess PARP enzyme inhibition and its effects on DNA repair processes. It enables researchers to monitor accumulation of DNA damage and evaluate the sensitivity of different cancer cell lines to PARP inhibition.

Such assays provide insights into cellular responses and help identify potential biomarkers associated with therapeutic sensitivity.

In Vivo

In vivo studies of Rucaparib camsylate have demonstrated its activity in tumor models, where it contributes to inhibition of cancer cell growth through disruption of DNA repair pathways. These studies are essential for understanding pharmacokinetic properties and therapeutic potential in complex biological systems.

The compound is frequently used in translational research to bridge in vitro findings with physiological responses observed in animal models.

Biochemical and Physiological Actions

The primary biochemical action of Rucaparib camsylate involves inhibition of PARP enzymes, particularly PARP1 and PARP2, which are essential for repairing single-strand DNA breaks. By blocking these enzymes, the compound leads to accumulation of DNA damage, ultimately promoting cell death in susceptible tumor cells.

From a physiological perspective, this mechanism is especially relevant in cancers with impaired DNA repair capacity, where PARP inhibition can selectively impact tumor cells while sparing normal tissues.

Features and benefits Rucaparib camsylate

Rucaparib camsylate offers a well-characterized pharmacological profile, making it suitable for a wide range of oncology research applications. When supplied as EBC-80069, it is supported by quality control and analytical validation, ensuring reliability in experimental workflows.

• selective inhibition of PARP enzymes for targeted research
• extensive use in DNA repair and oncology studies
• consistent quality supported by validated analytical data

As part of a comprehensive portfolio of bioactive molecules, Rucaparib camsylate enables researchers to investigate DNA damage response mechanisms and refine experimental approaches in cancer biology.